Patients were divided into two groups: group I included the RA patients with the higher disease activity as well as RF-positive, ACPA-positive and CVD presence; whereas group II included the RA patients with the lowest disease activity without RF, ACPA and CVD. The gene discussed is PRTN3; the disease is rheumatoid arthritis.